Skip to main content
Caplight Logo









Liberate Bio

Liberate Bio

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://liberatebio.com/

Last Round

Seed

Oct 15, 2025

Total Funding Raised

$31M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Liberate Bio is a biotechnology company developing a genetic medicine platform designed to enable targeted delivery of RNA therapies to immune cells beyond the liver.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Application

Keywords

lipid nanoparticlesLNPgenetic medicine deliveryextrahepatic deliveryin vivo screeningCAR-Mgenetic engineeringdrug delivery platformnucleic acid therapeuticsin vivo reprogrammingbiotech discovery platformgene therapy deliveryAI-driven drug discoverynon-viral deliverycell therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Liberate Bio Comparables

Compare Liberate Bio with similar companies based on industry and business-model similarity.

Liberate Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
MOTE Therapeutics
88%
Mana.bio
87%
Hopewell Therapeutics
87%

Liberate Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedOct 15, 2025

Key People

Founding team and executive leadership

Walter Strapps

Chief Scientific Officer

Executive Team

Liberate Bio Investors

Notable investors and investment history

Liberate Bio investors
InvestorRounds
Khosla VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors increased 61% MoM.

  • Jul 25, 2026

    Monthly visitors increased 83% MoM.

Liberate Bio Filings

Explore SEC and related filing metadata, where available.

Liberate Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Liberate Bio's valuation, stock price, and market status.

Is Liberate Bio a public or private company?

Liberate Bio is a private company.

What is the current stock price of Liberate Bio?

Liberate Bio is a private company with no public stock price. No recent secondary market data is available.

How much is Liberate Bio worth (valuation)?

Valuation information for Liberate Bio is not publicly available.

Can I buy Liberate Bio stock?

Liberate Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Liberate Bio's last funding round?

Liberate Bio's most recent funding round was Seed on October 15, 2025.

Who are the main investors in Liberate Bio?

Key investors in Liberate Bio include Khosla Ventures.

Will Liberate Bio IPO soon?

No public IPO plans have been announced for Liberate Bio.

How can I track Liberate Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Liberate Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range13
Year Founded2022
Last FundingOct 15, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?